Translational success stories: Angiotensin receptor 1 antagonists in heart failure

Circulation Research

Volumn 109, Issue 4, 2011, Pages 437-452

  Dell'italia, Louis J ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

angiotensin II; heart failure; hypertension

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN[1-12]; ANGIOTENSIN[1-7]; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR; CANDESARTAN; CAPTOPRIL; CARDIAC AGENT; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; G PROTEIN COUPLED RECEPTOR; GLYCERYL TRINITRATE; IRBESARTAN; LOSARTAN; NITROPRUSSIDE SODIUM; PERINDOPRIL; TELMISARTAN; TRV 120027; UNCLASSIFIED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CELL DEATH; COUGHING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DYSPNEA; ENZYME INHIBITION; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STROKE; THORAX PAIN;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HEART FAILURE; HUMANS; MYOCARDIUM; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; VENTRICULAR FUNCTION, LEFT;

EID: 80051715632     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.238550     Document Type: Review

References (196)

1. Tigerstedt R, Bergman PG. Niere und Kreislauf. Skand Arch Physiol. 1898;8:223-227.
2. Marks LS, Maxwell MH. Tigerstedt and the discovery of renin. An historical note. Hypertension. 1979;1:384-388.
3. Bright R. Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guys Hospital Rep. 1836;1:338.
4. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med. 1934;59:347-379.
5. Munoz MJ, Braun-Menendez E, Fasciolo JD, Leloir LF. Hypertensin: the substance causing renal hypertension. Nature. 1939;144:980.
6. Page IH, Helmer OM. A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. J Exp Med. 1940;71:29-42.
7. Kahn JR, Skeggs LT Jr, Shumway NP, Wisenbaugh PE. The assay of hypertensin from the arterial blood of normotensive and hypertensive human beings. J Exp Med. 1952;95:523-529.
8. Skeggs LT Jr, Marsh WH, Kahn JR, Shumway NP. Amino acid composition and electrophoretic properties of hypertensin I. J Exp Med. 1955;102:435-440.
9. Skeggs LT Jr, Lentz KE, Kahn JR, Shumway NP, Woods KR. The amino acid sequence of hypertension. II. J Exp Med. 1956;104:193-197.
10. Bumpus FMH, Schwarz H, Page IH. Synthesis and pharmacology of the octapeptide angiotonin. Science. 1957;125:887-891.
11. Levy D, Brink S. A Change of Heart. How the Framingham Heart Study Helped Unravel the Mysteries of Cardiovascular Diseases. New York, NY: Random House; 2005.
12. Goldring W, Chasis H. Antihypertensive drug therapy, In: Ingelfinger FJ, Rclman AS, Finland M, eds. Controversy in internal medicine. Philadelphia, PA: WB Saunders; 1966:83-91.
13. Veterans Administration Cooperative Study Group on Antihypertensive Agents: I. results in patients with diastolic blood pressure averaging 115-129 mm Hg. JAMA. 1967;202:116-122.
14. Freis ED. Reminiscences of the Veterans Administration trial on the treatment of hypertension. Hypertension. 1990;16:472-475. (Pubitemid 20338543)
15. Sarnoff SJ, Berglund E. Neurohemodynamics of pulmonary edema. IV. Effect of systemic vasoconstriction and subsequent vasodilatation on flow in systemic and pulmonary vascular beds. Am J Physiol. 1952;170:588-600.
16. Johnson JB, Gross JF, Hale E. Effects of sublingual administration of nitroglycerin on pulmonary-artery pressure in patients with failure of the left ventricle. N Eng J Med. 1957;257:1114-1117.
17. Johnson JB, Fairley A, Carter C. Effects of sublingual nitroglycerin on pulmonary arterial pressure in patients with left ventricular failure. Ann Int Med. 1959;50:34-42.
18. Zelis R, Mason DT. Compensatory mechanisms in congestive heart failure - the role of the resistance vessels. N Eng J Med. 1970;282:962-964.
19. Franciosa JA, Guiha NH, Limas CJ, Rodrigurera, Cohn JN. Improved left ventricular function during nitroprusside infusion in acute myocardial infarction. Lancet. 1972;1:650-654.
20. Gold HK, Leinbach RC, Sanders CA. Use of sublingual nitroglycerin in congestive failure following acute myocardial infarction. Circulation. 1972;46:839-845.
21. Majid PA, Siamba B, Taylor SH. Phentolamine for vasodilator treatment of severe heart-failure. Lancet. 1971;2:719-724.
22. Guiha NH, Cohn JN, Mikulic E, Franciosa JA, Limas C. Treatment of refractory heart failure with infusion of nitroprusside. N Eng J Med. 1974;291:587-592.
23. Cohn JN. Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation. 1973;48:5-8.
24. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: Renin and aldosterone, heart attack and stroke. N Eng J Med. 1972;286:441-449.
25. Brunner HR, H Gavras H, Laragh JH, Keenan R. Angiotensin-II blockade in man by Sar1-Ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet. 1973;2:1045-1048.
26. Gavras H, Flessas A, Ryan TJ, Brunner HR, Faxon DP, Gavras I. Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension. JAMA. 1977;238:880-892.
27. Turini GA, Brunner HR, Ferguson RK, Rivier JL, Gavras H. Congestive heart failure in normotensive man. Haemodynamics, renin, and angiotensin II blockade. Br Heart J. 1978;40:1134-1142.
28. Skeggs LT Jr, Kahn JR, Shumway NP. The preparation and function of the hypertensin-converting enzyme. J Exp Med. 1956;103:295-299.
29. Smith CG, Vane JR. The discovery of captopril. FASEB J. 2003;17:788-789. (Pubitemid 36538651)
30. Erdös EG. The ACE and I: how ACE inhibitors came to be. FASEB J. 2006;20:1034-1038. (Pubitemid 44943898)
31. Semple PF, Herd GW. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. N Engl J Med. 1986;314:61. (Pubitemid 16183077)
32. Fuller RW, Choudry NB. Increased cough reflex associated with angiotensin converting enzyme inhibitor cough. BMJ. 1987;295:1025-1026. (Pubitemid 17151254)
33. Hood S, Nicholls MG, Gilchrist NL. Cough with angiotensin converting-enzyme inhibitors. NZ Med J. 1987;100:6-7. (Pubitemid 17039903)
34. Coulter DM, Edwards IR. Cough associated with captopril and enalapril. BMJ. 1987;294:1521-1523. (Pubitemid 17108389)
35. Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Theory Prac. 1987; A9:243-259. (Pubitemid 17096549)
36. Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med. 2010;123:1016-1030.
37. Boucher R, Asselin J, Genest J. A new enzyme leading to the direct formation of angiotensin II. Circ Res. 1974;34:I.203-I.212.
38. Arakawa K, Ikeda M, Fukuyama J, Sakai TA. Pressor formation by trypsin from renin-denatured human plasma protein. J Clin Endocrinol Metabol. 1976;42:599-602.
39. Arakawa K, Maruta H. Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed 'kinin-tensin enzyme system.' Nature. 1980;288:705-706. (Pubitemid 11168524)
40. Tonnesen MG, Klempner MS, Austen KF, Wintroub BU. Identification of a human neutrophil angiotensin II-generating protease as cathepsin G. J Clin Invest. 1982;69:25-30. (Pubitemid 12212241)
41. Dzau VJ. Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J Hypertens. 1989;7:933-936. (Pubitemid 20106526)
42. Cornish KG, Joyner WL, Gilmore JP. Direct evidence for the presence of a different converting enzyme in the hamster cheek pouch. Circ Res. 1979;44:540-544. (Pubitemid 9170885)
43. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4:966-972. (Pubitemid 13204034)
44. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. 1990;66:883-890. (Pubitemid 20126420)
45. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357. (Pubitemid 120014308)
46. Furukawa Y, Kishimoto S, Nishikawa WA. Hypotensive Imidazole Derivatives and Hypotensive imidazole-5-acetic Acid Derivatives. Patents issued to Takeda Chemical Industries Ltd. on July 20, 1982, and October 19, 1982, respectively, U. 5. Patents 4, 340, 598 and 4, 355, 040, Osaka, Japan, 1952.
47. Bhardwaj G. How the antihypertensive losartan was discovered. Expert Opin Drug Discov. 2006;1:609-618.
48. Aumelas A, Sakarellos C, Lintner K, Fermandjian S, Khosla MC, Smeby RR, Bumpus FM. Studies on angiotensin II and analogs: impact of substitution in position 8 on conformation and activity. Proc Natl Acad Sci U S A. 1985;82:1881-1885. (Pubitemid 15060805)
49. Duncia JV, Chiu AT, Carini DJ, Gregory GB, Johnson AL, Price WA, Wells GJ, Wong PC, Calabrese JC Timmermans PB. The discovery of potent nonpeptide angiotensin II receptor antagonists: A new class of potent antihypertensives. J Med Chem. 1990;33:1312-1329. (Pubitemid 20148364)
50. Ganten D, Hayduk K, Brecht HM, Boucher R, Genest J. Evidence for renin release or production in splanchnic territory. Nature. 1970;226:551-552.
51. Symonds EM, Stanley MA, Skinner SL. Production of renin by in vitro cultures of human chorion and uterine muscle. Nature. 1968;217:1152-1153.
52. Ganten D, Minnich JL, Granger P, Hayduk K, Brecht HM, Barbeau A, Boucher R, Genest J. Angiotensin-forming enzyme in brain tissue. Science. 1971;173:64-65.
53. Ganten D, Hermann K, Bayer C, Unger T, Lang RE. Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science. 1983;221:869-871. (Pubitemid 13034290)
54. Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens. 1989;11:1325-1350. (Pubitemid 19228218)
55. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest. 1990;86:1913-1920.
56. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991;69:475-482.
57. Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res. 1993;73:439-447. (Pubitemid 23238728)
58. Baker KM, Chernin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol. 1990;259:H324-H332. (Pubitemid 20259406)
59. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
60. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Eng J Med. 1987;316:1429-1435.
61. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of congestive heart failure. N Eng J Med. 1991;325:303-310.
62. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N Eng J Med. 1991;325:293-302.
63. Dell'Italia LJ, Meng QC, Balcells E, Straeter-Knowlen IM, Hankes GH, Dillon R, Cartee RE, Orr R, Bishop SP, Oparil S, Elton TS. Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. Am J Physiol. 1995;269:H2065-H2073. (Pubitemid 26023225)
64. Weinberg EO, Lee MA, Weigner M, Lindpaintner K, Bishop SP, Benedict CR, Ho KK, Douglas PS, Chafizadeh E, Lorell BH. Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. Circulation. 1997;95:1592-1600. (Pubitemid 27142820)
65. Zisman LS, Asano K, Dutcher DL, Ferdensi A, Robertson AD, Jenkin M, Bush EW, Bohlmeyer T, Perryman MB, Bristow MR. Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart. Circulation. 1998;98:1735-1741. (Pubitemid 28492493)
66. Danser AH. Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol. 2003;35:759-768. (Pubitemid 36379316)
67. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-1427. (Pubitemid 34596167)
68. Dell'Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, Hageman GR, Durand J, Hankes GH, Oparil S. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest. 1997;100:253-258. (Pubitemid 27349070)
69. Nguyen G, Muller DN. The biology of the (pro) renin receptor. J Am Soc Nephrol. 2010;21:18-23.
70. Cousin C, Bracquart D, Contrepas A, Nguyen G. Potential role of the (pro) renin receptor in cardiovascular and kidney diseases. J Nephrol. 2010;23:508-513.
71. Danser AHJ. Cardiac angiotensin II: does it have a function? Am J Physiol. 2010;299:H304-H306.
72. Silver RB, Reid AC, Mackins CJ, Askwith T, Schaefer U, Herzlinger D, Levi R. Mast cells: a unique source of renin. Proc Natl Acad Sci U S A. 2004;101:13607-13612. (Pubitemid 39238450)
73. Reid AC, Silver RB, Levi R. Renin: at the heart of the mast cell. Immunol Rev. 2007;217:123-140. (Pubitemid 46718147)
74. Mackins CJ, Kano S, Seyedi N, Schäfer U, Reid AC, Machida T, Silver RB, Levi R. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest. 2006;116:1063-1070.
75. Singh VP, Le B, Bhat VB, Baker KM, Kumar R. High glucose induced regulation of intracellular angiotensin II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol. 2007;293:H939-H948. (Pubitemid 47254192)
76. Singh VP, Baker KM, Kumar R. Activation of the intracellular reninangiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol. 2008;294:H1675-H1684. (Pubitemid 351490598)
77. Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res. 2007;101:455-464. (Pubitemid 47347876)
78. Koka V, Wang W, Huang XR, Kim-Mitsuyama S, Truong LD, Lan HY. Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications. Circulation. 2006;113:1353-1360. (Pubitemid 43739457)
79. van Esch JH, Gembardt F, Sterner-Kock A, Heringer-Walther S, Le TH, Lassner D, Stijnen T, Coffman TM, Schultheiss HP, Danser AH, Walther T. Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts. Cardiovasc Res. 2010;86:401-409.
80. Booz GW, Conrad KM, Hess AL, Singer HA, Baker KM. Angiotensin-II-binding sites on hepatocyte nuclei. Endocrinology. 1992;130:3641-3649.
81. Tang SS, Rogg H, Schumacher R, Dzau VJ. Characterization of nuclear angiotensin-II-binding sites in rat liver and comparison with plasma membrane receptors. Endocrinology. 1992;131:374-380.
82. Re RN, Vizard DL, Brown J, Bryan SE. Angiotensin II receptors in chromatin fragments generated by micrococcal nuclease. Biochem Biophys Res Commun. 1984;119:220-227. (Pubitemid 14166742)
83. Fu ML, Schulze W, Wallukat G, Elies R, Eftekhari P, Hjalmarson A, Hoebeke J. Immunohistochemical localization of angiotensin II receptors (AT1) in the heart with anti-peptide antibodies showing a positive chronotropic effect. Receptors Channels. 1998;6:99-111. (Pubitemid 29057306)
84. Eggena P, Zhu JH, Clegg K, Barrett JD. Nuclear angiotensin receptors induce transcription of renin and angiotensinogen mRNA. Hypertension. 1993;22:496-501. (Pubitemid 23292155)
85. Gwathmey TM, Shaltout HA, Pendergrass KD, Pirro NT, Figueroa JP, Rose JC, Diz DI, Chappell MC. Nuclear angiotensin II type 2 (AT2) receptors are functionally linked to nitric oxide production. Am J Physiol. 2009;296:F1484-F1493.
86. Re RN. The intracellular renin angiotensin system: the tip of the intracrine physiology iceberg. Am J Physiol. 2007;293:H905-H906.
87. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: implications in cardiovascular remodeling. Curr Opinion Neph Hyper. 2008;17:168-173. (Pubitemid 351253042)
88. Trask AJ, Ferrario CM. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev. 2007;25:162-174. (Pubitemid 47035429)
89. Santos RA, Ferreira AJ, Simoes E Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp Physiol. 2008;93:519-527. (Pubitemid 351595060)
90. Fleming I, Kohlstedt K, Busse R. New fACEs to the renin-angiotensin system. Physiology. 2005;20:91-95. (Pubitemid 40627549)
91. Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29:394-400. (Pubitemid 27074074)
92. Wei CC, Ferrario CM, Brosnihan KB, Farrell DM, Bradley WE, Jaffa AA, Dell'Italia LJ. Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo. Pharmacol Exp Ther. 2002;300:324-329. (Pubitemid 34028543)
93. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-E9.
94. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970-976. (Pubitemid 38579900)
95. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensinconverting enzyme 2. Circulation. 2005;111:2605-2610. (Pubitemid 40740859)
96. Ferrario CM. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension. 2010;55:445-452.
97. Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan KB, Ferrario CM, Penninger JM, Batlle D. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2010;55:90-98.
98. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation. 2003;108:1707-1712. (Pubitemid 37243658)
99. Averill DB, Ishiyama Y, Chappell MC, Ferrario CM. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation. 2003;108:2141-2146. (Pubitemid 37337592)
100. Diez-Freire C, Va'zquez J, Correa de Adjounian MF, Ferrari MF, Yuan L, Silver X, Torres R, Raizada MK. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics. 2006;27:12-19. (Pubitemid 44511821)
101. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM, Raizada MK. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90:783-790. (Pubitemid 41406067)
102. der Sarkissian S, Grobe JL, Yuan L, Narielwala DR, Walter GA, Katovich MJ, Raizada MK. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension. 2008;51:712-718. (Pubitemid 351301525)
103. Donoghue M, Wakimoto H, Maguire CT, Acton S, Hales P, Stagliano N, Fairchild-Huntress V, Xu J, Lorenz JN, Kadambi V, Berul CI, Breitbart RE. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol. 2003;35:1043-1053. (Pubitemid 37083248)
104. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin- converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828. (Pubitemid 34670323)
105. Ferreira AJ, Santos RA, Bradford CN, Mecca AP, Sumners C, Katovich MJ, Raizada MK. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension. 2010;55:207-213.
106. Gwathmey TM, Pendergrass KD, Reid SD, Rose JC, Diz DI, Chappell MC. Angiotensin-(1-7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension. 2010;55:166-171.
107. Hernandez Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51:1312-1317. (Pubitemid 351555943)
108. Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun. 2006;350:1026-1031. (Pubitemid 44596223)
109. Jessup JA, Trask AJ, Chappell MC, Nagata S, Kato J, Kitamura K, Ferrario CM. Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol. 2008;294:H2614-H2618.
110. Trask AJ, Jessup JA, Chappell MC, Ferrario CM. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol. 2008;294:H2242-H2247.
111. Ferrario C, Varagic J, Hanini J, Nagata S, Kato J, Chappel MC, Trask AJ, Kitamura K, Whaley-Connel A, Sowers JR. Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol. 2009;296:H1184-H1192.
112. Prosser HC, Forster ME, Richards AM, Pemberton CJ. Cardiac chymase converts rat proAngiotensin-12 (PA12) to angiotensin II: effects of PA12 upon cardiac haemodynamics. Cardiovasc Res. 2009;82:40-50.
113. Ahmad S, Varagic J, Westwood BM, Chappell MC, and Ferrario CM. Uptake and metabolism of the novel Peptide Angiotensin-(1-12) by neonatal cardiac myocytes. PLoS One. 2011;6:e15759.
114. Esteban V, Ruperez M, Sánchez-López E, Rodríguez- Vita J, Lorenzo O, Demaegdt H, Vanderheyden P, Egido J, Ruiz-Ortega M. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res. 2005;96:965-973. (Pubitemid 40712796)
115. Fang KC, Raymond WW, Blount JL, Caughey GH. Dog mast cell alpha-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain. J Biol Chem. 1997;272:25628-25635. (Pubitemid 27438877)
116. Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem. 2005;280:9291-9296. (Pubitemid 40409621)
117. Okumura K, Takai S, Muramatsu M, Katayama S, Sakaguchi M, Kishi K, Jin D, Miyazaki M. Human chymase degrades human fibronectin. Clin Chim Acta. 2004;347:223-225.
118. Leskinen MJ, Lindstedt KA, Wang Y, Kovanen PT. Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arterioscler Thromb Vasc Biol. 2003;23:238-243. (Pubitemid 36231934)
119. Forteza R, Lauredo I, Abraham WM, Conner GE. Bronchial tissue kallikrein activity is regulated by hyaluronic acid binding. Am J Respir Cell Mol Biol. 1999;21:666-674. (Pubitemid 129502285)
120. Caughey GH. Mast cell tryptases and chymases in inflammation and host defense. Immunolog Rev. 2007;217:141-154. (Pubitemid 46718143)
121. Swedenborg J, Mäyränpää MI, Kovanen PT. Mast cells: Important players in the orchestrated pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2011;31:734-740.
122. Chandrasekharan UM, Sanker S, Glynias MJ, Karnik SS, Husain A. Angiotensin II-forming activity in a reconstructed ancestral chymase. Science. 1996;271:502-505.
123. Kakizoe E, Shiota N, Tanabe Y, Shimoura K, Kobayashi Y, Okunishi H. Isoform-selective upregulation of mast cell chymase in the development of skin fibrosis in scleroderma model mice. J Invest Dermatol. 2001;16:118-123. (Pubitemid 32108761)
124. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003;107:2555-2558. (Pubitemid 36628935)
125. Pat B, Chen Y, Killingsworth C, Gladden JD, Shi K, Zheng J, Powell PC, Walcott G, Ahmed MI, Gupta H, Desai R, Wei CC, Hase N, Kobayashi T, Sabri A, Granzier H, Denney T, Tillson M, Dillon AR, Husain A, Dell'Italia LJ. Chymase inhibition prevents fibronectin and myofibrillar loss and improves cardiomyocyte function and LV torsion angle in dogs with isolated mitral regurgitation. Circulation. 2010;122:1488-1495.
126. Jin D, Takai S, Sakaguchi M, Okamoto Y, Muramatsu M, Miyazaki M. An antiarrhythmic effect of a chymase inhibitor after myocardial infarction. J Pharmacol Exp Ther. 2004;309:490-497. (Pubitemid 38542599)
127. Jin D, Takai S, Yamada M, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Miyazaki M. Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res. 2003;60:413-420. (Pubitemid 37412375)
128. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM, Husain A. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91:1269-1281. (Pubitemid 23127321)
129. Wei CC, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, Naqvi N, Powell PC, Shi K, Takahashi Y, Saku K, Urata H, Dell'Italia LJ, Husain A. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest. 2010;120:1229-1239.
130. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1991;351:233-236. (Pubitemid 21896571)
131. Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature. 1991:351;230-233. (Pubitemid 21896570)
132. Iwai N, Yamano Y, Chaki S, Konishi F, Bardhan S Tibbetts C, Sasaki K, Hasegawa M, Matsuda Y, Inagami T. Rat angiotensin II receptor: cDNA sequence and regulation of the gene expression. Biochem Biophys Res Commun. 1991;177:299-304.
133. Iwai N, Inagami T. Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett. 1992;257-260.
134. Kakar SS, Sellers JC, Devor DC, Musgrove LC, Neill JD. Angiotensin II type-1 receptor subtype cDNAs: differential tissue distribution expression and hormonal regulation. Biochem Biophys Res Commun. 1992;183:1090-1096.
135. Sandberg K, Ji H, Clark AJ, Shapira H, Catt KJ. Cloning and expression of a novel angiotensin II receptor subtype. J Biol Chem. 1992;267:9455-9458.
136. Oro C, Qian H, Thomas WG. Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther. 2007;113:210-226. (Pubitemid 44969930)
137. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651-657.
138. Nakajima M, Hutchinson HG, Fuginaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Nat Acad Sci U S A. 1995;26:1401-1409.
139. Liu Y-H, Yang X-P, Sharov VG, Nass O, Sabbah HN, Peterson E, Carratero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonist in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest. 1997;99:192-1935.
140. Steckelings UM, Rompe F, Kaschina E, Namsolleck P, Grzesiak A, Funke-Kaiser H, Bader M, Unger T. The past, present and future of angiotensin II type 2 receptor stimulation. J Renin Ang Aldoster Syst. 2010;11:67-73.
141. Lemarie CA, Schriffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Ang Aldoster Syst. 2010;11:19-31.
142. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschöpe C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlöf B, Kintscher U, Unger T, Steckelings UM. Angiotensin type 2 receptor stimulation. A novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523-2532.
143. Gelosa P, Pignieri A, Fändriks L, de Gasparo M, Hallberg A, Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E, Sironi L. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444-2451.
144. Steckelings UM, Larhed M, Hallberg A, Widdop RE, Jones ES, Wallinder C, Namsolleck P, Dahlof B, Unger T. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol. 2011;11:187-192.
145. Kenakin T. Functional selectivity and biased receptor signaling. J Phamacol Exp Therapeut. 2011;336:296-302.
146. Patel CB, Noor N, Rockman HA. Functional Selectivity in Adrenergic and Angiotensin Signaling Systems. Molec Pharmacol. 2010;78:983-992.
147. Noor N, Patel CB, Rockman HA./3-Arrestin: A signaling molecule and potential therapeutic target for heart failure. J Moll Cell Cardiol. 2010 Nov. 11.
148. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK./3-arrestins and cell signaling. Annu Rev Physiol. 2007;69:483-510.
149. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov. 2010;9:373-386.
150. Sanni SJ, Hansen JT, Bonde MM, Speerschneider T, Christensen GL, Munk S, Gammeltoft S, Hansen JL. Beta-Arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct high-affinity conformations. Brit J Pharmacol. 2010;161:150-161.
151. Bonde MM, Hansen JT, Sanni SJ, Haunsø S, Gammeltoft S, Lyngsø C, Hansen JL. Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms. PLoS One. 2010;30:5:e14135.
152. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW. Selectively Engaging/3-Arrestins at the Angiotensin II Type 1 Receptor Reduces Blood Pressure and Increases Cardiac Performance. J Pharmacol Exp Therapeut. 2010;335:572-579.
153. Rakesh K, Yoo B, Kim I, Salazar N Kim K, Rockman HA./3-arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal. 2010;3:1-10.
154. Zhai P, Galeotti J, Liu J, Holle E, Yu X, Wagner T, Sadoshima J. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res. 2006;99:528-536. (Pubitemid 44337825)
155. Smith NJ, Chan HW, Qian H, Bourne AM, Hannan KM, Warner FJ, Ritchie RH, Pearson RB, Hannan RD, Thomas WG. Determination of the Exact Molecular Requirements for Type 1 Angiotensin Receptor Epidermal Growth Factor Receptor Transactivation and Cardiomyocyte Hypertrophy. Hypertension. 2011 Mar. 7.
156. Turu G, Szidonya L, Gaborik Z, Buday L, Spat A, Clark AJ, Hunyady L. Differential beta-arrestin binding of AT1 and AT2 angiotensin receptors. FEBS Lett. 2006;580:41-45. (Pubitemid 43005309)
157. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Int Med. 1997;157:2413-2446.
158. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
159. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomized trial of losartan versus captopril in patients over 65 with heart falure (Evaluation of Losartan in Elderly Study, ELITE). Lancet. 1997;349:747-752. (Pubitemid 27122456)
160. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failuar Survival Study ELITE II. Lancet. 2000;355:1582-1587. (Pubitemid 30240502)
161. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772-776. (Pubitemid 37093917)
162. Dickstein K, Kjekshus J. OPTIMAAL Steering committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Optimal therapy in myocardial infarction with angiotensin II antagonist losartan. Lancet. 2002;360:752-760. (Pubitemid 35247704)
163. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, et al. Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Eng J Med. 2003;349:1893-1906. (Pubitemid 37409706)
164. Rousseau MF, Konstam MA, Benedict CR, Donckier J, Galanti L, Melin J, Kinan D, Ahn S, Ketelslegers JM, Pouleur H. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long term therapy with angiotensin-converting enzyme inhibitors. Am J Cardiol. 1994;73:488-493.
165. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056-1064. (Pubitemid 29416231)
166. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771. (Pubitemid 37093916)
167. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Eng J Med. 2001;345:1667-1675. (Pubitemid 33126822)
168. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1-e90
169. and Circulation. 2009;19(14):e391-e479.
170. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, ESC Committee for Practice Guidelines (CPG). European Society of Cardiology; Heart Failure Association of the ESC (HFA); European Society of Intensive Care Medicine (ESICM). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933-989.
171. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajada M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Poole-Wilson PA, HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374:1840-1848.
172. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. (Pubitemid 29407370)
173. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Eng J Med. 2003;348:1309-1321. (Pubitemid 36384098)
174. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370:221-229. (Pubitemid 47069535)
175. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J, Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17-24.
176. Solomon SD, Hee Shin S, Shah A, Skali H, Desai A, Kober L, Maggioni AP, Rouleau JL, Kelly RY, Hester A, McMurray JJ, Pfeffer MA; for the Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. 2011;32:1227-1234.
177. Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJV, Desai A, Gimpelewicz C, Kandra A, Reimund B, Henning Rattunde H, Armbrecht J, ATMOSPHERE Investigators. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with Heart failuRE (ATMOSPHERE) study. Eur J Heart Fail. 2011;13:107-114.
178. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781. (Pubitemid 37093918)
179. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467.
180. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345. (Pubitemid 44453578)
181. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP, Valsartan In Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369:2079-2087. (Pubitemid 46935945)
182. Guder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Stork S. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754-1761. (Pubitemid 46648612)
183. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355-1364.
184. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901. (Pubitemid 23002899)
185. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosteroneinduced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773-1781. (Pubitemid 35265535)
186. du Cailar G, Fesler P, Ribstein J, Mimran A. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. Hypertension. 2010;56:865-870.
187. Acelajado MC, Pimenta E, Calhoun DA. Salt and aldosterone: a concert of bad effects. Hypertension. 2010;56:804-805.
188. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008;51:339-344. (Pubitemid 351159948)
189. Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54:475-481.
190. Mohammed SF, Ohtani T, Korinek J, Lam CS, Larsen K, Simari RD, Valencik ML, Burnett JC Jr, Redfield MM. Minearalocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". Circulation. 2010;122:370-378.
191. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation. 2005;111:871-878. (Pubitemid 40279888)
192. Sugimoto T, Tanigawa T, Onishi K, Fujimoto N, Matsuda A, Nakamori S, Matsuoka K, Nakamura T, Koji T, Ito M. Serum intact parathyroid hormone levels predict hospitalization for heart failure. Heart. 2009;95:395-398.
193. Borkowski BJ, Cheema Y, Shahbaz AU, Bhattacharya SK, Weber KT. Cation dyshomeostasis and cardiomyocyte necrosis: the Fleckenstein hypothesis revisited. Eur Hear J. March 12, 2011.
194. Zucker IH, Schultz HD, Patel KP, Wang W, Gao L. Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol. 2009;297:H1557-H1566.
195. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC, Muller DN. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension. 2008;51:682-688. (Pubitemid 351301521)
196. Pals DT, Masucci FD, Sipas F, Denning GS Jr. A specific competitive antagonist of the vascular action of angiotensin II. Circ Res. 1971;29:664-672.